Condition: Primary Immune Thrombocytopenia (ITP) · Sponsor: argenx
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · Clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital Scottsdale | Phoenix, Arizona, United States | Recruiting |
| University of Southern California Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Sharp Memorial Hospital | Oceanside, California, United States | Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Georgetown University Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| The University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| The University of Iowa Hospitals & Clinics | Iowa City, Iowa, United States | Recruiting |
| Tulane University | New Orleans, Louisiana, United States | Recruiting |
| Henry Ford Health | Detroit, Michigan, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Regional Cancer Care Associates, LLC (RCCA) | Little Silver, New Jersey, United States | Recruiting |
+ 82 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06544499